nuevolution

Nuevolution AB (publ) (ticker: NUE.ST), is a Scandinavian biopharmaceutical company focused on developing drug treatments for human diseases within oncology and chronic inflammatory diseases. We have set our focus and objectives to be: -Realization of efficacious, safer, tablet based, and lower cost medicines, for treatment of severe chronic inflammatory diseases where significant unmet medical need remains. -Realization of programs enabling future medicines in immuno-oncology, effectively reactivating the cancer patients own immune system, when this has been silenced by tumour cells. -Realization of programs enabling personalized medicine (medicine fitting the individual patient) for treatment of cancer through identification of drugs, which selectively and safely eliminate the biological pathways upon which the tumour cells (of the individual patient) are dependent for survival and growth. Nuevolution is the inventor of Chemetics®, a patent protected drug discovery platform, which enables efficient discovery of novel small molecule (tablet based) drug candidates. The platform provides access to screening of billions of molecules and efficient optimization of drug properties in the process of identifying the drug candidate. Chemetics® has been successfully applied in numerous drug discovery and technology licensing partnerships. Nuevolution has entered 17 agreements with partners including Amgen, Almirall, Novartis, Janssen Biotech, Inc. (Johnson & Johnson), Boehringer Ingelheim, GlaxoSmithKline, Merck & Co (MSD), Lexicon Pharmaceuticals, as well as world-class oncology research institutions, such as Cancer Research Technology and Institute of Cancer Research. The Company was founded in May 2001 and is headquartered in Copenhagen, Denmark. Forty-five dedicated and experienced full time employees work at Nuevolution. Nuevolution was listed on Nasdaq First North Premier in December 2015.